PARIS, July 5, 2011 /PRNewswire/ -- Cellectis bioresearch, a subsidiary of Cellectis (Alternext: ALCLS) and specialist in genome customization, has received the "Most Innovative New Service 2011" award from Select Biosciences for their TALEN® Access service offering. TALENs(1) allow for customized gene modifications, providing researchers across multiple disciplines with a powerful and now affordable new tool. This prize was presented at the Life Science Awards preceding the European Lab Automation conference held in Hamburg June 30 and July 1, 2011.
Each year the Life Science Awards celebrate the best of the industry's achievements worldwide. The awards are judged by a panel of international industrial and academic experts.
"We are very honored to receive this award. It rewards well our team's tremendous work in coming up with such an extremely high quality offer at an affordable price, only a few months after having acquired the technology," stated Dr. Luc Selig, VP Sales and Marketing at Cellectis bioresearch.
"We are the first to market TALEN® and are bringing in new clients every day," added Marc Le Bozec, CEO of Cellectis bioresearch. "Our ambition is to convert biology researchers around the world to genome customization. This community of 3 million is now exploring this completely new approach that allows them to better do things they were already doing, but most importantly opens up so many new possibilities. We estimate the market potential to be in the millions of euro within 10 years."
Today, TALEN® Access is paired with individualized project management support to better meet the needs of Cellectis bioresearch clients.
(1) TALEN: Transcription Activator-Like Effector Nuclease
About Cellectis bioresearch
Cellectis bioresearch was incorporated as a subsidiary of Cellectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready-
Copyright©2010 PR Newswire.
All rights reserved